Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index

This study investigated the effects of switching from combination therapy with either alogliptin (Alo) or pioglitazone (Pio) to fixed-dose combination therapy (FDCT) with alogliptin and pioglitazone (Alo-Pio FDCT). The usefulness and efficacy of Alo-Pio FDCT were investigated. A total of 50 outpatie...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Chie, Suzuki, Kunihiro, Kuroda, Hisamoto, Sagara, Masaaki, Shimizu, Masanori, Kasai, Kikuo, Aso, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346615/
https://www.ncbi.nlm.nih.gov/pubmed/28303056
http://dx.doi.org/10.18999/nagjms.79.1.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346615/
https://www.ncbi.nlm.nih.gov/pubmed/28303056
http://dx.doi.org/10.18999/nagjms.79.1.9

Ejemplares similares